Inhibikase announces common stock and warrants offering, no amount given

Inhibikase Therapeutics (IKT) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities being sold in the proposed offering are being offered by Inhibikase. Jefferies, BofA Securities and Cantor are acting as joint book-running managers for the proposed offering. LifeSci Capital and Oppenheimer & Co. are acting as co-lead managers for the proposed offering. H.C. Wainwright & Co. and Ladenburg Thalmann & Co. are acting as co-managers for the proposed offering.